Chen Keping, Li Ying, Yang Chuankun, Xiao Peng, Li Guochun, Xu Yurong
Clinical Laboratory, Zhongda Hospital, School of Medicine, Southeast University Nanjing 210009, Jiangsu, China.
Nanjing Central Hospital, Nanjing Municiple Government Hospital Nanjing 210009, Jiangsu, China.
Am J Cardiovasc Dis. 2023 Aug 15;13(4):264-271. eCollection 2023.
Genetic factors contribute to the variability in individual response to antihypertensive medications. We sought to investigate the frequencies of allele and genotype for and genetic polymorphisms and explore their potential impact in influencing the selection of antihypertensive beta-receptor blockers.
The study population was selected from the Han Chinese patients in Zhongda Hospital, which contained 2419 Han Chinese hypertensive individuals and 151 normotensive controls. Each of the above participants underwent venous blood sampling. Then, the gene chip platform was adopted to evaluate the and genetic polymorphisms. The allele as well as genotype frequencies for each gene, along with the combined genotypes, were subjected to analysis.
The frequency of *1/*1 wild-type homozygous for was 9.71%, while the frequency of *1/*10 heterozygous or *10/*10 mutant homozygous was 59.16% or 31.13%, respectively, as established by gene chip analysis. Similarly, we observed that the genotype frequencies of GG wild-type homozygous for was 10.29%, while that of GC heterozygous, or CC mutant homozygous was 44.98%, or 44.73%, respectively. Notably, combined genotypes *1/*10 + CC (25.88%) and *1/*10 + CG (27.78%) had the highest frequencies. Importantly, no substantial differences in the distributions of and polymorphism were noted between hypertensive patients and normotensive controls, or among all different grades of hypertension.
These findings provide insights into the and polymorphisms in hypertensive patients from Han Chinese, which show significant differences compared to other geographic groups of Han Chinese hypertensive patients. These results offer valuable information for future prospective clinical studies on the antihypertensive effects of beta-receptor blockers in Han Chinese hypertensive patients.
遗传因素导致个体对抗高血压药物的反应存在差异。我们旨在研究β1和β2基因多态性的等位基因和基因型频率，并探讨它们在影响抗高血压β受体阻滞剂选择方面的潜在影响。
研究人群选自中大医院的汉族患者，包括2419名汉族高血压个体和151名血压正常对照。上述每位参与者均接受静脉采血。然后，采用基因芯片平台评估β1和β2基因多态性。对每个基因的等位基因和基因型频率以及联合基因型进行分析。
基因芯片分析确定，β1基因*1/1野生型纯合子的频率为9.71%，而1/10杂合子或10/10突变型纯合子的频率分别为59.16%或31.13%。同样，我们观察到β2基因GG野生型纯合子的基因型频率为10.29%，而GC杂合子或CC突变型纯合子的频率分别为44.98%或44.73%。值得注意的是，联合基因型1/10 + CC（25.88%）和1/*10 + CG（27.78%）的频率最高。重要的是，在高血压患者和血压正常对照之间，或在所有不同级别的高血压患者中，未观察到β1和β2多态性分布的实质性差异。
这些发现为汉族高血压患者的β1和β2多态性提供了见解，与其他地理区域的汉族高血压患者群体相比存在显著差异。这些结果为未来关于汉族高血压患者中β受体阻滞剂降压作用的前瞻性临床研究提供了有价值的信息。
